Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENP-501 in Non-Peanut Allergic and Peanut Allergic Participants
NCT07117669Phase 2Recruiting
- Start
- Dec 2025
- Primary completion
- Nov 2028
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in peanut allergy comparing ENP-501 with Placebo (2 arms). Primary endpoints: Number of Participants with Treatment-Emergent Adverse Events up to 22 Weeks, Number of Participants with Treatment-Emergent Serious Adverse Events up to 22 Weeks and 6 more. Started Dec 2025; status: recruiting.
02
Drugs
ENP-501
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT07117669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07117669.